$0.00
Shopping Cart
Facebook-f Instagram
Donate

Clinical Trial Record

Return to Clinical Trials

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

2018-06-08

2026-07

2026-12

82

Study Overview

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

This is an open-label, Phase I, FTIH, multiple-dose, dose-escalation and cohort expansion multi-center study conducted in three parts to identify a safe and pharmacologically active dose and regimen for VMD-928 monotherapy, which can be implemented in Phase 2 studies (the RP2D). The regimen will be identified using an adaptive design, multiple-ascending dose study in cancer patients. To conserve patients in the lower dose cohorts, dose escalation will begin with an accelerated titration scheme. A second part of the study will assess antitumor activity at the RP2D. The third part of the study will collect tumor samples before and after treatment to assess biological activity.

  • Head and Neck Carcinoma
  • Adenoid Cystic Carcinoma
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Pancreatic Cancer
  • Mesothelioma
  • Thymic Carcinoma
  • Cervical Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Esophageal Cancer
  • Uterine Cancer
  • Sarcoma
  • Any Solid Tumors Progressed After a Prior Immunotherapy
  • Thymoma
  • Appendiceal Cancer
  • Olfactory Neuroblastoma
  • DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
  • VMO-01C

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2018-04-29  

N/A  

2025-04-15  

2018-06-01  

N/A  

2025-04-17  

2018-06-14  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

  • Taken orally once daily
Primary Outcome MeasuresMeasure DescriptionTime Frame
Number and severity of treatment-emergent AEsWithin 2 cycles (each cycle is 28 days)
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Area under the plasma concentration versus time curve (AUC) of VMD-928.On Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
Peak plasma concentration (Cmax) of VMD-928.On Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
Incidence of Dose Limiting Toxicities.During the Cycle 1 (each cycle is 28 days)
Analgesic response as defined by the Brief Pain Inventory (BPI).On Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
Change in TrkA protein expression.Pre-dose and at the end of Cycle 2 (each cycle is 28 days)
Correlation between clinical antitumor and AUC.Up to the end of the Cycle 2 (each cycle is 28 days)
Correlation between clinical antitumor and TrkA protein expression.Up to the end of the Cycle 2 (each cycle is 28 days)
Correlation between analgesic response and TrkA protein expression.Up to the end of the Cycle 2 (each cycle is 28 days)
Correlation between analgesic response and AUC.Up to the end of the Cycle 2 (each cycle is 28 days)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Jay Wu, PhD

Phone Number: 1-510-270-2790

Email: OM@VMOncology.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Key Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.
  • ECOG score of 0 or 1.
  • Able to swallow and retain oral medication.
  • Adequate organ system function.
  • Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose, that is sufficient for IHC analysis of TrkA expression, except with prior documented NTRK+.
  • Subjects must have a tumor:

    • (i). with TrkA protein overexpression (TrkA+) in the validated TrkA IHC assay, OR (ii). with documented NTRK1 gene fusion (NTRK1+) including a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor (e.g. larotrectinib or entrectinib)
  • Adequate organ system function as defined as follows:

    • 1. Absolute neutrophil count ≥1.5x10^9/L 2. Hemoglobin ≥9g/dL 3. Platelets ≥100x10^9/L 4. PT/INR, PTT ≤1.5xULN 5. Total bilirubin ≤1.5x ULN 6. AST, ALT ≤2.5xULN 7. Creatinine ≤1.2xULN for age, weight 8. Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL/min
    Key Exclusion Criteria:
    1. Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C). 2. Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks. 3. Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor. 4. Unresolved toxicity from previous anticancer therapy > CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator. 5. Negative result on TrkA immunohistochemistry (IHC) assay (if enrolled in dose expansion cohorts). 6. Known active infections including HIV disease. 7. Patients with a history of chronic viral hepatitis (HBV/HCV), even if treated, or a history of cirrhotic liver secondary to any etiology (i.e. alcoholism, non-alcoholic steatohepatitis). 8. Currently pregnant, nursing, or planning to become pregnant during the course of the study. 9. QTcF interval ≥ 480 msec. 10. Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. 11. Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks. 12. Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug. 13. Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded. 14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drug, or excipients. 15. Patient has had or is currently having other malignant tumors within 3 years. 16. Patients have multiple factors that affect their oral medication. 17. Patients have long-term unhealed wounds or fractures. 18. Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. 19. Patients are taking the following drugs and can't stop them during the study:

  • Tylenol or medicine containing acetaminophen (paracetamol).
  • Strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • STUDY_CHAIR: Clinical Development, VM Oncology

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶
    footer logo

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate